ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2995

WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients

Martijn H. van den Bosch1, Arjen B. Blom1, Azusa Maeda2, Tina Kilts2, Wim B. van den Berg3, Peter L. van Lent3, Marian F. Young2 and Peter M. van der Kraan1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2NIDCR/NIH, Bethesda, MD, 3Radboud university medical center, Nijmegen, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: matrix metalloproteinase (MMP), osteoarthritis and synovium, WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Biology and Pathology of Bone and Joint

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Many osteoarthritis (OA) patients show synovial activation, which is thought to be involved in joint destruction. Previously, we described strongly increased expression of Wnt2b and Wnt16 in the synovium of two experimental OA models. In addition, we found increased Wisp1 expression, a protein induced by canonical Wnt signaling. Here, we determined whether there is a relation between synovial WISP1 expression and OA progression in a cohort study of patients with early symptomatic OA. Furthermore, we elucidated whether WISP1 plays a role during experimental OA by inducing OA models in wild type (WT) and Wisp1-/-mice.

Methods:  Microarray analysis was performed on synovium from patients in the CHECK study, initiated to follow progression of early symptomatic OA patients. Expression data were correlated with progression of OA (defined as a decrease in joint space width of ≥1mm and progression of osteophyte formation of ≥4x in size) between baseline and the five-year follow-up measurement. Human end-stage OA synovium was stimulated with WISP1. Joint pathology in WT or Wisp1-/-mice was assessed by histology after induction of collagenase-induced OA (CIOA), destabilization of the medial meniscus (DMM) and anterior cruciate ligament transection (ACLT) experimental models of OA. The aggrecan neoepitope NITEGE was visualized using immunohistochemistry. Gene expression was evaluated using qRT-PCR.

Results:  Microarray analysis of synovial tissue from patients in the CHECK cohort showed significantly increased WISP1 expression at baseline in OA progressors versus non-progressors. To determine the mechanism of how WISP1 might be involved in OA pathology, we stimulated human OA synovium with WISP1. This increased the expression of MMP2/3/9/13 and ADAMTS4/5. Next, we determined the in vivo role of WISP1. First, we found that spontaneous cartilage damage was not different between WT and Wisp1-/- mice at 3, 6 and 12 months of age. Next, we assessed joint pathology 42 days after induction of CIOA. Cartilage damage was significantly decreased in the tibio-femoral joints of the Wisp1-/- mice as compared with the WT controls. In line, we found significantly decreased cartilage degeneration in the Wisp1-/- mice in the DMM and ACLT models, 56 days after induction. In addition we found decreased expression of Mmp3/9 and the aggrecanases Adamts4/5 in the synovium, 7 days after induction of CIOA in Wisp1-/- mice, in line with the increased expression of these factors after stimulation of human OA synovium with WISP1. Whereas Wisp1-/- mice showed decreased expression of the protease inhibitor Timp1, the expression of Timp3, an important inhibitor of ADAMTS4/5, was unaffected. Finally, the protease activity in the cartilage, as assessed by the staining of the neoepitope NITEGE, was decreased in the Wisp1-/-mice.

Conclusion:  Increased WISP1 expression may play an important role in OA pathology via increased synovial MMP/ADAMTS expression. Furthermore, because of the tight regulation and complexity of Wnt signaling and its role in many physiological processes, targeting WISP1 may more specifically target OA-related pathological events, while minimizing interference with physiological processes.


Disclosure: M. H. van den Bosch, None; A. B. Blom, None; A. Maeda, None; T. Kilts, None; W. B. van den Berg, None; P. L. van Lent, None; M. F. Young, None; P. M. van der Kraan, None.

To cite this abstract in AMA style:

van den Bosch MH, Blom AB, Maeda A, Kilts T, van den Berg WB, van Lent PL, Young MF, van der Kraan PM. WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/wisp1ccn4-aggravates-experimental-osteoarthritis-and-is-associated-with-disease-progression-in-early-osteoarthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/wisp1ccn4-aggravates-experimental-osteoarthritis-and-is-associated-with-disease-progression-in-early-osteoarthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology